0.01
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Acrux
Its shares trade on ASX under the ticker ACR.AX. It has been listed since 29 September 2004. In the fiscal year to 30 June 2026, it reported revenue of A$4.6m and a net loss of A$604,000. At that date it held total assets of A$6.8m and shareholders' equity of A$1.5m.
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The firm's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. The company has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The firm has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Sept 2004
- Employees
- 43
Leadership
Pay as last reported
- Mr. Ross DobinsonIndependent Non-Executive Chairman of the Board, since 1998A$131,114
- Mr. Michael KotsanisChief Executive Officer, Managing Director, Executive Director, since 2014A$701,959
- Ms. Joanna JohnsonChief Financial Officer, Company SecretaryA$298,616
- Ms. Felicia ColagrandeProduct Development and Technical Affairs DirectorA$295,971
- Mr. Mark HymanProject and Technical Development DirectorA$285,109
- Dr. Geoffrey BrookeIndependent Non-Executive DirectorA$84,654
- Mr. Donald BrumleyIndependent Non-Executive DirectorA$84,012
- Dr. Timothy OldhamIndependent Non-Executive DirectorA$84,654
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 54
- Social
- 34
- Governance
- 57
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Acrux Ltd possesses several strengths that contribute to its success in the market:
- Despite its strengths, Acrux Ltd also faces certain weaknesses that need to be addressed:
- Acrux Ltd can capitalize on the following opportunities to expand its market share:
- Acrux Ltd should be cautious of the following threats in the market:
Weaknesses
- Despite its strengths, Acrux Ltd also faces certain weaknesses that need to be addressed:
- Acrux Ltd can capitalize on the following opportunities to expand its market share:
- Acrux Ltd should be cautious of the following threats in the market:
Opportunities
- Acrux Ltd can capitalize on the following opportunities to expand its market share:
- Acrux Ltd should be cautious of the following threats in the market:
Threats
- Acrux Ltd should be cautious of the following threats in the market:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.